Sustained cell-mediated but not humoral responses in rituximab-treated rheumatic patients after vaccination against SARS-CoV-2.

Konstantinos Thomas,Ioannis Grigoropoulos, Panagiota Alexopoulou,Emmanouil Karofylakis, Eirini Galani, Kyriaki Korina Papadopoulou,Anastasia Tsiavou, Aliki Ntourou, Eleftheria Mavrou, Irina Qevani,Pelagia Katsimbri,Christos Koutsianas,Evgenia Mavrea,Dimitrios Vassilopoulos, Spyros Pournaras,Sotirios Tsiodras,Dimitrios Boumpas,Anastasia Antoniadou

Rheumatology (Oxford, England)（2023）

引用 0|浏览0

暂无评分

摘要

Four out of ten RTX-treated vaccinated patients show lasting cell-mediated immune response despite undetectable anti-spike antibodies. Cumulative RTX dose affects both humoral and cell-mediated responses to SARS-CoV-2 vaccines. Cell-mediated immune responses call for attention as a vaccine efficacy marker against SARS-CoV-2.

查看译文

关键词

rituximab,SARS-CoV-2,cell-mediated immunity,breakthrough infection

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要